Life Science Investing Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
Life Science Investing Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Life Science Investing Interim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
Life Science Investing Ambrx Announces NovoCodex's Dosing of First Patient with ARX305, Ambrx's Investigational Antibody Drug Conjugate Targeting CD70
Life Science Investing Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update
Life Science Investing Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
Life Science Investing Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
